Is Lexapro (escitalopram) safe to use while breastfeeding?

Lexapro Safety During Breastfeeding

Lexapro (escitalopram) is generally safe to use while breastfeeding, with sertraline and paroxetine being preferred first-line alternatives, but escitalopram remains an acceptable option when clinically indicated.

Key Safety Data

Infant Drug Exposure

Escitalopram transfers into breast milk but results in minimal infant exposure:

• The relative infant dose (total drug exposure to infant as percentage of maternal dose) is approximately 5.3% for escitalopram plus its metabolite 1, well below the generally accepted safety threshold of 10%
• More recent pharmacokinetic modeling confirms infant plasma exposure is only 1.7% (median, range 0.5-5.9%) of maternal plasma levels 2
• Infant plasma concentrations are typically undetectable (below 3 mcg/L) in most breastfed infants despite measurable milk concentrations 1
• The milk-to-plasma ratio is approximately 2.2, meaning higher concentrations in milk than maternal blood, but the absolute infant dose remains low at 7.6 mcg/kg/day 1

Clinical Outcomes in Breastfed Infants

Most infants tolerate maternal escitalopram use without adverse effects:

• The FDA label acknowledges reports of excessive sedation, restlessness, agitation, poor feeding, and poor weight gain in some exposed infants 3
• However, systematic reviews and prospective studies show no adverse neurodevelopmental outcomes in infants breastfed by mothers on SSRIs 4
• In clinical studies, all breastfed infants met normal developmental milestones with no observed adverse effects 1

Comparative Safety Among Antidepressants

Sertraline and paroxetine are preferred over escitalopram during breastfeeding:

• Systematic reviews identify sertraline and paroxetine as first-line choices with superior neonatal safety profiles 5
• Recent data confirms sertraline and paroxetine result in mostly undetectable infant plasma levels, while citalopram (escitalopram's parent compound) shows detectable levels in 4 of 13 infants 6
• Escitalopram may be preferred over racemic citalopram due to lower absolute infant dose at equivalent antidepressant efficacy 1

Clinical Management Recommendations

Monitoring Requirements

If prescribing escitalopram during breastfeeding, implement specific infant monitoring:

• The FDA mandates advising mothers to monitor infants for sleepiness, fussiness, poor feeding, and inadequate weight gain 3
• Contact healthcare provider immediately if these symptoms develop 3
• Regular weight and growth monitoring should be performed, as decreased appetite and weight loss are associated with SSRI use 3

Treatment Considerations

When maternal mental health treatment is necessary:

• Priority should be given to effectively treating the mother, as untreated maternal depression poses significant risks to the mother-infant dyad 4
• Continue medications that were effective during pregnancy when possible 4
• Use the lowest effective dose and consider timing doses immediately after breastfeeding to minimize infant exposure 7
• The benefits of breastfeeding generally outweigh theoretical medication risks when SSRIs are clinically indicated 6, 7

Important Caveats

Key limitations and considerations:

• While escitalopram appears safe based on available data, fewer studies exist compared to sertraline and paroxetine 5, 8
• The FDA label notes that developmental and health benefits of breastfeeding should be weighed against maternal clinical need and potential infant effects 3
• Long-term neurodevelopmental follow-up data remain limited for all SSRIs during lactation 5
• Each decision requires individual risk-benefit analysis considering maternal illness severity, treatment response history, and infant factors 1

In summary: Escitalopram can be used during breastfeeding when clinically necessary, though sertraline or paroxetine are preferred alternatives. Infant monitoring for sedation, feeding difficulties, and growth is essential. 3, 5, 1, 6